Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Francine M. Foss, Youn H. Kim, H. Miles Miles Prince, Timothy M. Kuzel, Costas K. Yannakou, Chean Eng Ooi, Dongyuan Xing, Nicholas Sauter, Preeti Singh, Myron Czuczman, Madeleine Duvic

Blood (2022) 140 (Supplement 1): 1491–1492.

https://doi.org/10.1182/blood-2022-166916

Published: 2022

Journal Articles

Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

H. Miles Miles Prince, Larisa J Geskin, Oleg E Akilov, Timothy M. Kuzel, Christiane Querfeld, Chean Eng Ooi, Dongyuan Xing, Nicholas Sauter, Preeti Singh, Myron Czuczman, Francine M. Foss

Blood (2022) 140 (Supplement 1): 6577–6578.

https://doi.org/10.1182/blood-2022-167564

Published: 2022

Journal Articles

Four-Fold Increased Mortality from Sars-Cov-2 Infection in Patients with Hematologic Versus Non-Hematologic Malignancies Treated at the Largest Tertiary COVID-19 Center in Chicago/Rush University Medical Center (March 1, 2020-December 31,2020)

Nicole K. Yun, Praneeth Chebrolu, Paul R. Yarnold, Joshua Thomas, James L. Coggan, Anmol Baranwal, Charles L. Bennett, Ankur Varma, Timothy M. Kuzel

Blood (2021) 138 (Supplement 1): 1947.

https://doi.org/10.1182/blood-2021-149694

Published: 2021

Journal Articles

Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study

Swaminathan P Iyer, Auris Huen, Weiyun Z. Ai, Deepa Jagadeesh, Mary Jo Lechowicz, Craig Okada, Tatyana A. Feldman, Suchitra Sundaram, Juan Pablo Alderuccio, Nishitha Reddy, Don Stevens, Timothy M. Kuzel, Ann Mohrbacher, Kasi Viswanath Routhu, Prajak Barde, Ajit Mohanchandran Nair, Brad M. Haverkos

Blood (2021) 138 (Supplement 1): 1365.

https://doi.org/10.1182/blood-2021-145851

Published: 2021

Journal Articles

A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

Swami P. Iyer, MD, Auris Huen, MD, Bradley Haverkos, MD MPH, MS, Weiyun Z. Ai, Craig Okada, MD PhD, Timothy M. Kuzel, MD, Mary Jo Lechowicz, MD, Juan Pablo Alderuccio, MD, Ann Mohrbacher, MD, Don A. Stevens, MD, Ryan A. Wilcox, MD, Tatyana A. Feldman, MD, Suchitra Sundaram, MD, Deepa Jagadeesh, MDMPH, Nishitha Reddy, MD MSCI, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-136018

Published: 2020

Journal Articles

A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma

Ayad Al-Katib, MD, Timothy M. Kuzel, MD, Ralph Parchment, PhD

Blood (2019) 134 (Supplement_1): 4041.

https://doi.org/10.1182/blood-2019-127278

Published: 2019

Journal Articles

First Report of Severe Folate Deficiency in Women Treated with Olaparib for Relapsed Ovarian Cancer

Jamile M. Shammo, MD, Lydia Usha, MD, Kristin Richardson, MD, Elizabeth Jane Elliott, BS, DO, Parameswaran Venugopal, MD, Timothy M. Kuzel, MD, Melody Cobleigh, MD, Summer Dewdney, MD

Blood (2017) 130 (Supplement 1): 4748.

https://doi.org/10.1182/blood.V130.Suppl_1.4748.4748

Published: 2017

Journal Articles

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

Blood (2017) 130 (Supplement 1): 1509.

https://doi.org/10.1182/blood.V130.Suppl_1.1509.1509

Published: 2017

Journal Articles

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

Madeleine Duvic, MD, Timothy M Kuzel, MD, Nam H. Dang, MD PhD, Miles Prince, MD FRACP, FRCPA, Tatyana Feldman, MD, Francine M. Foss, MD, Matthew Guo, PhD, Lone Harild Ottesen, MD PhD, Chean Eng Ooi, PhD, Youn H Kim, MD

Blood (2014) 124 (21): 3097.

https://doi.org/10.1182/blood.V124.21.3097.3097

Published: 2014

Journal Articles

Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome

Christiane Querfeld, Steven T. Rosen, Joan Guitart, Madeleine Duvic, Youn H. Kim, Stephen W. Dusza, Timothy M. Kuzel

Blood (2014) 123 (8): 1159–1166.

https://doi.org/10.1182/blood-2013-09-525915

Published: 2014

Journal Articles

The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden.

Madeleine Duvic, MD, Youn H Kim, MD, Timothy M Kuzel, MD, Theresa R Pacheco, MD, Francine M Foss, Sareeta Parker, Syed Rizvi, Cong Chen, Jean Marie Arduino, ScD, Elise A. Olsen, MD

Blood (2009) 114 (22): 1709.

https://doi.org/10.1182/blood.V114.22.1709.1709

Published: 2009

Journal Articles

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial.

Madeleine Duvic, MD, Youn H. Kim, MD, Timothy M. Kuzel, MD, Theresa R. Pacheco, MD, Francine M. Foss, MD, Sareeta Parker, MD, Stanley R. Frankel, MD, Cong Chen, PhD, Justin L. Ricker, MD, PhD, Jean Marie Arduino, PhD, Sophia Randolph, MD, PhD, Victoria M. Richon, PhD, Elise A. Olsen, MD

Blood (2006) 108 (11): 399.

https://doi.org/10.1182/blood.V108.11.399.399

Published: 2006

Journal Articles

Concurrent Treatment with Denileukin Diftitox (DD) To Deplete T-Regulatory Cells Enhances Rebound Lymphocytosis and Eosinophilia in Patients Treated with High-Dose IL-2 (HDIL-2) for Metastatic Renal Cell Cancer (MRCC).

Adi Gidron, MD, John Eklund, MD, Brenda Martone, RN, MSN, Alfred W. Rademaker, PhD, Charles Goolsby, PhD, Laura Marszalek, Timothy M. Kuzel, MD

Blood (2006) 108 (11): 1729.

https://doi.org/10.1182/blood.V108.11.1729.1729

Published: 2006

Journal Articles

Alemtuzumab (Campath-1H) in Patients with Erythrodermic Cutaneous T-Cell Lymphoma (E-CTCL): The Northwestern University Experience.

Christiane Querfeld, MD, Steven T. Rosen, MD, Joan Guitart, MD, Brenda Martone, RN, MSN, Alfred Rademaker, PhD, Timothy M. Kuzel, MD

Blood (2006) 108 (11): 2732.

https://doi.org/10.1182/blood.V108.11.2732.2732

Published: 2006

Journal Articles

Preliminary Results of a Phase II Study of CC-5013 (Lenalidomide, Revlimid®) in Patients with Cutaneous T-Cell Lymphoma.

Christiane Querfeld, MD, Timothy M. Kuzel, MD, Joan Guitart, MD, Steven T. Rosen, MD

Blood (2005) 106 (11): 3351.

https://doi.org/10.1182/blood.V106.11.3351.3351

Published: 2005

Journal Articles

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

Blood (2005) 106 (10): 3343–3347.

https://doi.org/10.1182/blood-2005-02-0508

Published: 2005

Journal Articles

FDA Policies Should Be Amended To Allow Pharmaceutical Manufacturers To Disseminate Information Regarding Potentially Fatal Toxicities That Occur with Off-Label Use of Oncology Agents: A Policy Recommendation Based on Review of Thalidomide-Associated Thromboembolism Cases by the RADAR Project.

Andrew M. Evens, DO, Martin S. Tallman, MD, Seema Singhal, MD, June M. McKoy, MD, JD, E. Allison Lyons, BA, Dennis W. Raisch, PhD, Paul R. Yarnold, PhD, Hau Kwaan, MD, Timothy M. Kuzel, MD, Jayesh Mehta, MD, Charles L. Bennett, MD, PhD

Blood (2004) 104 (11): 265.

https://doi.org/10.1182/blood.V104.11.265.265

Published: 2004

Journal Articles

Long-Term Follow-Up of 98 Cases of Recombinant Human Erythropoietin (epoetin) Induced Pure Red Cell Aplasia (PRCA): Outcomes and Treatment Data from the Research on Adverse Drug Reactions and Reports (RADAR) Program.

Kenneth R. Carson, MD, Stephen A. Klinge, BA, Steven M. Belknap, MD, June M. McKoy, MD, JD, MPH, Dennis W. Raisch, PhD, Martin S. Tallman, MD, Timothy M. Kuzel, MD, Andrew M. Evans, MD, Benjamin Kim, MD, Paul R. Yarnold, PhD, Elizabeth A. Lyons, BA, Charles L. Bennett, MD, PhD

Blood (2004) 104 (11): 5320.

https://doi.org/10.1182/blood.V104.11.5320.5320

Published: 2004

Journal Articles

Phase I Trial of a Ligand Fusion-Protein (DAB 389 IL-2) in Lymphomas Expressing the Receptor for Interkeukin-2

C.F. LeMaistre, Mansoor N. Saleh, Timothy M. Kuzel, Francine Foss, Leonidas C. Platanias, Gary Schwartz, Mark Ratain, Alain Rook, Cesar O. Freytes, Fiona Craig, James Reuben, Jean C. Nichols

Blood (1998) 91 (2): 399–405.

https://doi.org/10.1182/blood.V91.2.399

Published: 1998

Journal Articles

Recurring Structural Chromosome Abnormalities in Peripheral Blood Lymphocytes of Patients With Mycosis Fungoides/Sézary Syndrome

Maya Thangavelu, William G. Finn, Krishna K. Yelavarthi, Henry H. Roenigk, Jr, Ellen Samuelson, LoAnn Peterson, Timothy M. Kuzel, Steven T. Rosen

Blood (1997) 89 (9): 3371–3377.

https://doi.org/10.1182/blood.V89.9.3371

Published: 1997

NARROW

Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Four-Fold Increased Mortality from Sars-Cov-2 Infection in Patients with Hematologic Versus Non-Hematologic Malignancies Treated at the Largest Tertiary COVID-19 Center in Chicago/Rush University Medical Center (March 1, 2020-December 31,2020)

Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study

A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma

First Report of Severe Folate Deficiency in Women Treated with Olaparib for Relapsed Ovarian Cancer

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome

The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden.

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial.

Concurrent Treatment with Denileukin Diftitox (DD) To Deplete T-Regulatory Cells Enhances Rebound Lymphocytosis and Eosinophilia in Patients Treated with High-Dose IL-2 (HDIL-2) for Metastatic Renal Cell Cancer (MRCC).

Alemtuzumab (Campath-1H) in Patients with Erythrodermic Cutaneous T-Cell Lymphoma (E-CTCL): The Northwestern University Experience.

Preliminary Results of a Phase II Study of CC-5013 (Lenalidomide, Revlimid®) in Patients with Cutaneous T-Cell Lymphoma.

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

FDA Policies Should Be Amended To Allow Pharmaceutical Manufacturers To Disseminate Information Regarding Potentially Fatal Toxicities That Occur with Off-Label Use of Oncology Agents: A Policy Recommendation Based on Review of Thalidomide-Associated Thromboembolism Cases by the RADAR Project.

Long-Term Follow-Up of 98 Cases of Recombinant Human Erythropoietin (epoetin) Induced Pure Red Cell Aplasia (PRCA): Outcomes and Treatment Data from the Research on Adverse Drug Reactions and Reports (RADAR) Program.

Phase I Trial of a Ligand Fusion-Protein (DAB 389 IL-2) in Lymphomas Expressing the Receptor for Interkeukin-2

Recurring Structural Chromosome Abnormalities in Peripheral Blood Lymphocytes of Patients With Mycosis Fungoides/Sézary Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only